Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor

Annals of Oncology

Volumn 12, Issue 8, 2001, Pages 1151-1155

  Rick, O ^a   Beyer, J ^b   Schwella, N ^a   Schubart, H ^a   Schleicher, J ^c   Siegert, W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c KATHARINENHOSPITAL   (Germany)

Author keywords

Amifostine; Chemotherapy induced toxicity; Germ cell tumor; High dose chemotherapy

Indexed keywords

AMIFOSTINE; AMPHOTERICIN; ANTIBIOTIC AGENT; CARBOPLATIN; CEFOTAXIME; CIPROFLOXACIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MEROPENEM; PACLITAXEL; PIPERACILLIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOXICITY; FOLLOW UP; GERM CELL TUMOR; HEARING IMPAIRMENT; HUMAN; LIVER TOXICITY; MOTOR DYSFUNCTION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SKIN TOXICITY; STEM CELL TRANSPLANTATION;

ADULT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PACLITAXEL; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS; TAXOIDS;

EID: 0034831135     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011628900089     Document Type: Article

References (14)

1. Germ cell tumors: Dose-intensive therapy
2. Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine
3. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy
4. Evaluation of long-term toxicity after chemotherapy for testicular cancer
5. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer: A randomized phase II study
6. Amifostine pretreatment for protection against cyclophosphamide and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
7. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumor cells is maintained
8. Amifostine and dose-intense paclitaxel in patients with advanced malignancies
9. Randomized trial of carboplatin plus amifostine vs. carboplatin alone in patients with advanced solid tumors
10. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial
11. Blood progenitor cell mobilization with paclitaxel (Taxol®) in patients with germ cell cancer
12. Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer
13. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I-II study
14. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer